Whole-exome sequencing analysis of primary tumours and peritoneal metastatic lesions indicated that these metastatic lesions had a higher frequency of TP53 and CDH1 mutations and a lower response rate to chemotherapy (Wang et al. 2020). The gene discussed is TP53; the disease is neoplasm.